1. DOP51 Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patients. (30th January 2023) Authors: Hageman, I; Joustra, V; Zafeiropoulou, K; Davids, M; Hakvoort, T; Probert, F; Satsangi, J; D'Haens, G; De Jonge, W Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP03 Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn's disease patients: The EPIC-CD study. (30th January 2023) Authors: Joustra, V; Li Yim, A; Hageman, I; Levin, E; Noble, A; Chapman, T; McGregor, C; Adams, A; Satsangi, J; de Jonge, W; Henneman, P; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP29 Peripheral blood DNA methylation biomarkers accurately predict clinical- and endoscopic response to vedolizumab in a real-life cohort of Crohn's Disease patients. (21st January 2022) Authors: Joustra, V; Hageman, I; Li Yim, A; Levin, E; Satsangi, J; Adams, A; De Jonge, W; Henneman, P; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i032 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM. (25th January 2019) Authors: Yzet, C; Ungaro, R; Bossuyt, P; Baert, F; Vanasek, T; D'Haens, G; Joustra, V; Panaccione, R; Novacek, G; Armuzzi, A; Golovchenko, O; Prymak, O; Goldis, A; Travis, S; Hébuterne, X; Ferrante, M; Rogler, G; Fumery, M; Danese, S; Rydzewska, G Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S024 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P103 Identifying CES-1 positive myeloid cells with mass cytometry as a potential therapeutic target for Crohn's disease. (21st January 2022) Authors: Hageman MD, I; Elfiky, A; Becker, M; Joustra, V; Buskens, C; Li Yim, A; Hakvoort, T; Verhoeff, J; Garcia Vallejo, J; D'Haens, G; Wildenberg, M; De Jonge, W Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P198 An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn's Disease. (21st January 2022) Authors: Radford-Smith, D; Yates, A; Hageman, I; Joustra, V; Li Yim, A; Davids, M; Henneman, P; Hakvoort, T; D'Haens, G; de Jong, W; Anthony, D; Satsangi, J; Probert, F Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P707 Microbial signature of the colon is not associated with response to vedolizumab in Crohn's disease. (21st January 2022) Authors: Hageman, I; Joustra, V; Li Yim, A; Davids, M; Henneman, P; Hakvoort, T; Probert, F; Satsangi, J; D'Haens, G; De Jonge, W Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P803 Plasma N-glycan biomarkers predict patient Response to Vedolizumab treatment for Crohn's Disease. (30th January 2023) Authors: Elgood Hunt, G; Adams, A; Senard, T; Gardner, R; Jonge, W; Li Yim, A; Noble, A; Satsangi, J; Joustra, V; D'Haens, G; Spencer, D Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i936 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗